This database contains 23 studies, archived under the term: "mental disorders"
Click here to filter this large number of results.
Effect of second-generation antipsychotics on caregiver burden in Alzheimer’s disease
Mohamed, Somaia,
Rosenheck, Robert,
Lyketsos, Constantine G.,
Kaczynski, Richard,
Sultzer, David L.,
Schneider, Lon S.
Background: Alzheimer’s disease (AD) imposes a severe burden upon patients and their caregivers. Severity of psychiatric symptoms and behavioral disturbances is an important determinant of caregivers’ experience of burden. These symptoms may be improved with atypical antipsychotic treatment.; Objective: Data from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease (CATIE-AD) trial were used to evaluate […]
Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg
Herrschaft, Horst,
Nacu, Anatol,
Likhachev, Sergey,
Sholomov, Ilya,
Hoerr, Robert,
Schlaefke, Sandra
A multi-centre, double-blind, randomised, placebo-controlled, 24-week trial with 410 outpatients was conducted to demonstrate efficacy and safety of a 240 mg once-daily formulation of Ginkgo biloba extract EGb 761(®) in patients with mild to moderate dementia (Alzheimer’s disease or vascular dementia) associated with neuropsychiatric symptoms. Patients scored 9 to 23 on the SKT cognitive battery, […]
The implementation of the serial trial intervention for pain and challenging behaviour in advanced dementia patients (STA OP!): a clustered randomized controlled trial
Pieper, Marjoleine J. C.,
Achterberg, Wilco P.,
Francke, Anneke L.,
van der Steen, Jenny T.,
Scherder, Erik J.A.,
Kovach, Christine R.
Background: Pain (physical discomfort) and challenging behaviour are highly prevalent in nursing home residents with dementia: at any given time 45-80% of nursing home residents are in pain and up to 80% have challenging behaviour. In the USA Christine Kovach developed the serial trial intervention (STI) and established that this protocol leads to less discomfort […]
A randomized clinical trial of theory-based activities for the behavioral symptoms of dementia in nursing home residents
Kolanowski, Ann,
Litaker, Mark,
Buettner, Lin,
Moeller, Joyel,
Costa, Paul T., Jr.
Objectives: To test the main and interactive effects of activities derived from the Need-Driven Dementia-Compromised Behavior model for responding to behavioral symptoms in nursing home residents.; Design: Randomized double-blind clinical trial.; Setting: Nine community-based nursing homes.; Participants: One hundred twenty-eight cognitively impaired residents randomly assigned to activities adjusted to functional level (FL) (n=32), personality style […]
Prognostic factors for a favourable long-term outcome from an integrative psychotherapeutic nursing home programme
Bakker, Ton J. E. M.,
Duivenvoorden, Hugo J.,
van der Lee, Jacqueline,
Olde Rikkert, Marcel G. M.,
Beekman, Aartjan T. F.,
Ribbe, Miel W.
Background/aims: The prevalence of multiple psychiatric symptoms (MPS) in psychogeriatric patients is about 80%. MPS have negative effects on caregivers; 70-80% of caregivers are moderately to heavily burdened. We tested an integrative psychotherapeutic programme (IRR) focused on MPS as well as caregiver burden. To develop decision rules in indicating IRR, prognostic potentialities of diagnostic and […]
Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes
Weintraub, Daniel,
Rosenberg, Paul B.,
Drye, Lea T.,
Martin, Barbara K.,
Frangakis, Constantine,
Mintzer, Jacobo E.,
Porsteinsson, Anton P.,
Schneider, Lon S.,
Rabins, Peter V.,
Munro, Cynthia A.,
Meinert, Curtis L.,
Lyketsos, Constantine G.
Background: Depression and antidepressant use are common in Alzheimer disease (AD), but the effect of antidepressant treatment for depression on longer term outcomes is unknown. The authors report the Week-24 outcomes of patients who participated in a 12-week efficacy study of sertraline for depression of AD.; Methods: One hundred thirty-one participants (sertraline = 67, placebo […]
Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients: the CATIE-AD study
Zheng, Ling,
Mack, Wendy J.,
Dagerman, Karen S.,
Hsiao, John K.,
Lebowitz, Barry D.,
Lyketsos, Constantine G.,
Stroup, T. Scott,
Sultzer, David L.,
Tariot, Pierre N.,
Vigen, Cheryl,
Schneider, Lon S.
Objective: The second-generation antipsychotics are associated with metabolic abnormalities in patients with schizophrenia. Elderly patients with Alzheimer’s disease are frequently treated with these antipsychotics, but limited data are available on their metabolic effects.; Method: The authors assessed 186 male and 235 female Alzheimer’s disease outpatients from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease (CATIE-AD) […]